Characteristic,NME**,Biologic,Vaccine
Phase I to phase II,50.6%,52.5%,52%
Phase II to phase III,25.6%,32.4%,32.2%
Phase III to NDA/BLA*,50.6%,56.7%,58.1%
NDA/BLA to approval*,86.1%,94.6%,100%
